Immunogenicity: The New Stream For 2012
Immunogenicity: The New Stream For 2012
Oxford Global Conferences are proud to announce a brand new stream at the 5th Annual Proteins Congress. Delegates attending the Immunogenicity & Aggregation stream, will join the leading figures in protein development as they come together to discuss one of the industry’s most rapidly evolving fields. The stream has been designed to offer much needed clarity to anyone battling with the following challenges:
- How do we mitigate potential immunogenicity issues?
- How do we navigate immunogenicity concerns in the development of immunotherapeutics?
- How can we increase drug safety through a better understanding of immunogenicity?
- What are the necessary steps to take in early protein development?
Although organisations may still be struggling to fully understand immunogenicity, its potential impact on safety and efficacy cannot be ignored. Through a series of presentations by those working at the forefront of immunogenicity testing, profiling and mitigation, we aim to explore how executives from large and small pharma are tackling immunogenicity and what can be learned from their academic counterparts. Our senior level, expert speakers include Joel Richard, VP Drug Product Development at Ipsen, David Meininger, Senior Director Biologics Discovery at Merck and Michel Awwad, Senior Director at Pfizer.
      
|